Some people experience weight gain during treatment with Vraylar. While exercise may be helpful, it’s crucial not to overheat or dehydrate. Taking Vraylar can affect your metabolism, such as ...

Vraylar (cariprazine) is a powerful antipsychotic medication that is approved by the Food and Drug Administration (FDA) to treat schizophrenia, bipolar disorder, and major depressive disorder (MDD).

Many people with major depressive disorder don’t get enough relief from their symptoms despite antidepressant medication. To potentially rectify the problem, the U.S. Food and Drug Administration (FDA ...

Vraylar (cariprazine) is a prescription drug that helps treat certain mental health conditions. The drug comes as an oral capsule. Vraylar may not be safe to take while pregnant or breastfeeding. Keep ...

It’s not known whether Vraylar is safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether you should ...

A patient with depression says she was "stuck" until AbbVie's Vraylar gave her "a lift," which is the theme of the company's latest ad campaign for the mental health drug. Vraylar, a sales blockbuster ...

The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy. The Food and Drug ...

Allergan plcAGN and Hungary-based partner Gedeon Richter Plc. have announced positive top-line results from the third pivotal study, evaluating the companies' schizophrenia drug Vraylar (cariprazine) ...

They worked together before on bipolar medication Vraylar, and now Allergan—ahem, AbbVie—will try to repeat that success with Gedeon Richter. AbbVie, which of course absorbed Allergan two years ago, ...

- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant ...

Amidst AbbVie's $63 billion takeover of Allergan, much has been made of likely business drivers like Botox and eye drug Restasis. But another Allergan med—the next-gen antipsychotic Vraylar—is ...